Editas Medicine Inc Stock Price, News & Analysis

Editas Medicine (NASDAQ: EDIT) has reported promising new in vivo data for its gene editing therapy targeting sickle cell disease and beta thalassemia. The study demonstrated high efficiency in editing HBG1/2 promoters in hematopoietic stem cells (HSCs) using their proprietary targeted lipid nanoparticle (tLNP) delivery system. Key findings include:

In non-human primates, a single intravenous dose achieved up to 47% HBG1/2 editing levels in HSCs. In humanized mice, the treatment reached 48% editing in long-term HSCs. Both results exceeded the 25% threshold required for therapeutic benefit.

The company's tLNP formulation showed improved liver de-targeting compared to standard LNPs, and utilizes proprietary AsCas12a technology for high-efficiency editing while minimizing off-target effects. The approach mimics naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH).

Editas Medicine (NASDAQ: EDIT) presented promising in vivo proof of concept data for an undisclosed liver target at the ASGCT Annual Meeting. The study demonstrated successful gene editing using lipid nanoparticles with CRISPR/Cas RNA cargo. Key results include:

• ~70% maximal liver editing and >80% disease biomarker reduction in mouse models
• >50% target gene editing and >15-fold protein upregulation in cynomolgus monkey hepatocytes

The editing strategy mimics a naturally occurring protective variant to upregulate the target gene. The company plans to reveal the specific disease target and development candidate later in 2025. Additional data will be presented at the TIDES USA 2025 Conference.

Editas Medicine (NASDAQ: EDIT) reported Q1 2025 financial results and business updates. The company posted a net loss of $76.1 million ($0.92/share) compared to $62.0 million in Q1 2024. Cash position stands at $221.0 million, providing runway into Q2 2027. Key highlights include upcoming presentations of preclinical data at ASGCT, demonstrating successful use of targeted lipid nanoparticles for gene editing delivery. The company appointed Amy Parison as CFO and remains on track to declare two in vivo gene editing development candidates in mid-2025. Research and development expenses decreased to $26.6 million from $48.8 million YoY, while restructuring charges of $40.9 million were recorded related to the discontinuation of the reni-cel program.

Editas Medicine (NASDAQ: EDIT) announced that the U.S. Court of Appeals for the Federal Circuit has partially affirmed and partially vacated the Patent Trial and Appeal Board's (PTAB) previous decision regarding CRISPR/Cas9 patent interference. The case involves patents between the University of California, University of Vienna, and Emmanuelle Charpentier versus the Broad Institute.

The company emphasized that its in-licensed CRISPR/Cas12a patents are unaffected by this decision. Editas holds exclusive licenses to Harvard and Broad Institute's Cas9 patent estates for human medicine development. The company maintains a robust IP portfolio including fundamental patents for both CRISPR/Cas12a and CRISPR/Cas9 gene editing in human cells across multiple jurisdictions including the US, Europe, China, and Japan.

Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced it will release its Q1 2025 financial results on May 12, 2025 through a press release and SEC filings. The company has discontinued its practice of hosting quarterly financial results conference calls.

Additionally, Editas management will participate in the Bank of America Global Healthcare Conference in Las Vegas on May 13, 2025 at 5:15 p.m. PT in a fireside chat format. The presentation will be accessible via webcast on the company's website, with a replay available for approximately 30 days.

Editas Medicine (Nasdaq: EDIT) announced the acceptance of five abstracts for presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), scheduled for May 13-17, 2025, in New Orleans.

The presentations include:

• An oral presentation on in vivo preclinical data using targeted lipid nanoparticles for HBG1/2 promoter editing
• Preclinical proof of concept for a liver target using CRISPR editing
• Results from mouse and non-human primate studies showing high levels of target gene editing in the liver
• Data on guide modification and targeting improvements for better gene editing outcomes

Linda C. Burkly, Executive Vice President and Chief Scientific Officer, highlighted the company's progress in developing in vivo medicines. The research demonstrates their ability to increase protein levels to address diseases caused by loss of function or mutations through gene upregulation editing strategy. Their targeted lipid nanoparticle delivery system shows promise for multiple tissue applications using a 'plug 'n play' approach.

Editas Medicine (Nasdaq: EDIT) announced a leadership transition as Chief Financial Officer Erick J. Lucera will step down effective March 28, 2025, to pursue an external opportunity. Amy Parison, current Senior Vice President of Finance, has been appointed as the new CFO.

Parison brings over 18 years of financial, accounting, and business development experience in life sciences to the role. During her two-and-a-half-year tenure at Editas, she has been instrumental in equity financings, licensing transactions, and royalty monetization. Her previous experience includes positions at Rubius Therapeutics as Corporate Controller and various roles at Vertex Pharmaceuticals.

CEO Gilmore O'Neill praised Parison's financial decision-making, accounting acumen, and team leadership abilities, while acknowledging Lucera's contributions in positioning Editas financially and developing talent.

Editas Medicine (NASDAQ: EDIT) reported its Q4 and full year 2024 financial results, highlighting progress in its in vivo gene editing programs. The company remains on track to declare two development candidates in mid-2025: one for hematopoietic stem cells (HSCs) and another for liver cells.

Financial highlights include:

• Q4 2024 net loss of $45.4 million ($0.55 per share)
• Full year 2024 net loss of $237.1 million ($2.88 per share)
• Cash position of $269.9 million as of December 31, 2024
• Operational runway extended into Q2 2027

The company discontinued development of reni-cel program in December 2024, resulting in a 65% workforce reduction. Restructuring charges of $12.2 million were recorded in Q4 2024. The company's strategic focus has shifted to becoming a leader in in vivo gene editing, with promising preclinical data showing potential for gene upregulation across multiple tissues.

Editas Medicine (NASDAQ: EDIT) has announced it will release its Q4 and Full Year 2024 financial results and business updates on March 5, 2025, through a press release and SEC filings. The company has decided to discontinue hosting quarterly financial results conference calls.

The company's management team will participate in three major healthcare investor conferences in March: the TD Cowen 45th Annual Health Care Conference in Boston on March 3, the Leerink Partners Global Healthcare Conference in Miami on March 10, and the Barclays 27th Annual Global Healthcare Conference in Miami on March 11. All presentations will be in a fireside chat format and will be accessible via webcast on the company's website for approximately 30 days after each event.